BAKER BROS. ADVISORS LP

Q2 2025 13F Holdings

  • Location
    new york, NY
  • Num holdings

    89

  • Value ($000)

    $10,307,840

  • Date Filed
    08/14/2025
  • Form type
    13F-HR
  • CIK
    0001263508
  • All SEC filings
  • Note
    Holdings aggregated across “other managers” listed in original SEC filing, see here for detailed holdings broken out by other managers
Compare Q2 2025 to
Select Quarter
Issuer Name
Class
CUSIP
VALUE
%
Shares
Principal
Option Type
BGNE
BGNE

BeOne Medicines Ltd.

SPONSORED ADS
07725L102
$2.13B
21 %

8,799,053

INCY
INCY

Incyte Corporation

COM
45337C102
$2.09B
20 %

30,743,275

ACAD
ACAD

ACADIA Pharmaceuticals Inc.

COM
004225108
$925.28M
9 %

42,896,690

INSM
INSM

Insmed Incorporated

COM PAR $.01
457669307
$776.23M
8 %

7,712,900

SMMT
SMMT

Summit Therapeutics Inc.

COM
86627T108
$717.62M
7 %

33,722,974

MDGL
MDGL

Madrigal Pharmaceuticals, Inc.

COM
558868105
$598.02M
6 %

1,976,018

RYTM
RYTM

Rhythm Pharmaceuticals, Inc.

COM
76243J105
$354.15M
3 %

5,604,483

RVMD
RVMD

Revolution Medicines, Inc.

COM
76155X100
$344.54M
3 %

9,364,972

KYMR
KYMR

Kymera Therapeutics, Inc.

COM
501575104
$290.27M
3 %

6,651,429

---

Alkermes plc

SHS
G01767105
$183.41M
2 %

6,410,603

Rows Per Page
10
  • 10
  • 50
  • 100
1 - 10 of 89